# Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

> **NCT07167329** · PHASE2 · RECRUITING · sponsor: **José Claudio Casali da Rocha** · enrollment: 100 (estimated)

## Conditions studied

- Von Hippel Lindau
- Von Hippel Lindau Disease
- Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
- Hemangioblastoma (HB) of the Central Nervous System (CNS)
- PNET
- Retinal Angiomatous Proliferation
- Pheochromocytoma/Paraganglioma
- Endolymphatic Sac Tumor

## Interventions

- **DRUG:** Belzutifan

## Key facts

- **NCT ID:** NCT07167329
- **Lead sponsor:** José Claudio Casali da Rocha
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167329, "Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07167329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*